1. Home /
    2. Altai Protocol Library /
  2. New Protocol: Pembrolizumab + chemotherapy for previously untreated advanced triple-negative breast cancer

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Protocol: Pembrolizumab + chemotherapy for previously untreated advanced triple-negative breast cancer

New Protocol: Pembrolizumab + chemotherapy for previously untreated advanced triple-negative breast cancer
Study:
  • Placebo controlled phase 3 trial
  • Previously untreated locally recurrent inoperable or metastatic triple negative breast cancer
  • Pembrolizumab + chemo (n=566) vs. Placebo + chemo (n=281)
  • Chemo: Weekly PACLitaxel or weekly nab-PACLitaxel or CARBOplatin/gemcitabine
Efficacy:
  • Median PFS:
  • 7.5 vs. 5.6 mos in ITT population (NS)
  • 9.7 vs. 5.6 mos in CPS >= 10 (HR:0.65 [0.49-0.86])
Safety:
  • Grade 3-4 immune-mediated AEs: 5.5% vs. 0%
Journal of Clinical Oncology 2020;38(15_suppl):1000

Cortes J, et al. KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.

https://doi.org/10.1200/JCO.2020.38.15_suppl.1000

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More